Alnylam Pharmaceuticals reported 75.64 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
Acadia Pharmaceuticals 11.33 1.25 Jun/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 75.64 4.4 Jun/2026
Amgen 18.07 1.77 Jun/2026
Arrowhead Research 39.19 2.48 Mar/2026
BioCryst Pharmaceuticals 6.84 0.78 Jun/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Incyte 14.45 0.9 Jun/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 22.1 5.99 Jun/2026
Novartis 21.36 3.57 Mar/2026
PTC Therapeutics 8.76 1.22 Mar/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Sanofi 20.87 5.12 Mar/2026
Sarepta Therapeutics 27.27 0 Mar/2026
Takeda 24.4 22.12 Jun/2026
Tectonic Therapeutic 4.01 0.63 Mar/2024
Vertex Pharmaceuticals 28.05 2.22 Jun/2026
Xencor 29.92 3.22 Sep/2022